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Background and Objectives: Magnetic resonance imaging of the pelvis has a limited
accuracy to detect positive lymph nodes but does dictate neoadjuvant treatment in
rectal cancer. This study aimed to investigate preoperative lymph node understaging
and its effects on postoperative local recurrence rate.
Methods: Patients were selected from a retrospective cross‐sectional snapshot
study. Patients with emergency surgery, cM1 disease, or unknown cN‐ or (y)pN
category were excluded. Clinical and pathologic N‐categories were compared and
the impact on local recurrence was determined by multivariable analysis.
Results: Out of 1548 included patients, 233 had preoperatively underestimated lymph
node staging based on (y)pN category. Out of the 695 patients staged cN0, 168 (24%)
had positive lymph nodes at pathology, and out of the 594 patients staged cN1,
65 (11%) were (y)pN2. Overall 3‐year local recurrence rate was 5%. Clinical N‐category
was not associated with local recurrence when corrected for pT‐category, neoadjuvant
therapy, and resection margin, neither in patients with (y)pN1 (hazard ratio [HR]: 1.67
(95% confidence interval [CI]: 0.68‐4.12) P = .263) nor (y)pN2‐category (HR: 1.91 95%
CI: [0.75‐4.84], P = .175).
Conclusion: Preoperative understaging of nodal status in rectal cancer is not
uncommon. No significant effect on local recurrence or overall survival rates were
found in the present study.
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1 | INTRODUCTION
Over the past decades, total mesorectal excision (TME) and neoad-
juvant therapy have been associated with reduced local recurrence
rates in patients undergoing surgery for rectal cancer.1‐3 With
improved quality of TME surgery over time, the absolute contribution
of radiotherapy to locoregional control has diminished, especially in
early‐stage cancers.4 For this reason, indications for neoadjuvant
therapy in patients intentionally undergoing TME surgery have
changed over time, with improved balance between potential onco-
logical benefit and radiotherapy related morbidity.5
Preoperative locoregional staging of rectal cancer is currently
performed using magnetic resonance imaging (MRI), and these results
dictate the neoadjuvant treatment regimen.6‐9 The large randomized
trials on neoadjuvant therapy regimens did not routinely use MRI in the
preoperative staging, and inclusion was often based on tumor fixity as
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determined by digital rectal examination.10 MRI has made substantial
contributions to optimize patient selection and to tailor treatment.11
However, preoperative clinical staging using MRI has some restrictions,
especially accuracy for suspected positive lymph nodes is limited.9,12,13
Furthermore, since organ preserving surgery and nonsurgical manage-
ment for rectal cancer are gaining prominence, adequate staging might
become even more important in the future.
This study aimed to investigate the number of patients who
underwent surgical resection for rectal cancer with a preoperative
underestimated lymph node category and to analyze the effects of
nodal understaging on local recurrence rates.
2 | METHODS
All data were obtained from the Dutch Snapshot Research Group which
was described in detail previously.14 All 71 participating hospitals ret-
rospectively added long term follow‐up data to the prospective short‐
term data collected through the Dutch Surgical Colorectal Audit for all
consecutive patients who underwent resection of primary rectal cancer
in 2011. Only elective cases were included in the analyses since staging
might not be fully completed in patients who require emergency sur-
gery. Patients with M1 disease were excluded, as well as patients with
missing or undefined cN or (y)pN category. The study was approved by
the Medical Ethics Committee of the Amsterdam University Medical
Center and the need for individual informed consent was waived.
2.1 | Staging
Staging included an abdominal computed tomography (CT)‐scan, thoracic
X‐ray, and in most patients a pelvic MRI. The fifth edition TNM staging
was applied, because this version was used during the study period in
Dutch hospitals.15 Based on this edition, patients were classified as N0 in
the absence of lymph node metastasis, as N1 in case of up to three
regional tumor positive lymph nodes, and N2 for four of more positive
nodes. The national guideline‐recommended considering lymph nodes
positive when their size was equal to or greater than 5mm on MRI
images. Tumor nodules in the perirectal adipose tissue without lymphatic
tissue were regarded as lymph node metastases when the diameter
exceeded 3mm at pathology. Positive non‐regional lymph nodes were
staged as M1 disease. The national guideline of 2008, which was still valid
in 2011, recommended neoadjuvant radiotherapy for all cT2‐4 tumors,
with the exception of proximal cT2N0 tumors. Chemoradiotherapy could
be considered for cT3/4 and cN2 categories, while short‐course radio-
therapy was recommended for the remaining patients.
2.2 | Variables
Low anterior resection was defined as a TME with the formation of an
anastomosis, with or without diverting stoma. Abdominoperineal
resection was defined as a rectal resection according to TME principles
including the anal sphincter complex with a permanent colostomy. Low
Hartmann's procedure was defined as a (low) anterior resection with
closure of the rectal stump and the formation of an end colostomy. Any
disease recurrence in the pelvis, at the anastomosis, or in the perineal
wound was defined as local recurrence. Recurrence at other locations
not present at the time of rectal resection was defined as distant
recurrence and termed metastasis‐free survival within the current
study. Metastasis‐free survival and local recurrence‐free survival were
defined as the time from surgery to recurrence or last follow‐up. Overall
survival was defined as the time from surgery to death or last follow‐up.
2.3 | Statistical analysis
All continuous variables were displayed as median with interquartile
range, with the exception of hazard ratios for which the 95% confidence
interval was reported. Categorical variables were reported as numbers
with percentages and differences were tested using χ2 tests. Survival
curves were generated using the Kaplan‐Meier method, and differences
between groups were tested using logrank tests. Multivariable analyses
were performed using the Cox‐proportional hazard method. For local
recurrence and metastasis‐free survival, the effect of clinical nodal
staging was corrected for pT‐category (dichromate variable (y)pT0‐2 vs
(y)pT3‐4), positive resection margin, and neoadjuvant treatment regi-
men. These variables were considered the main factors to influence the
risk of (local) recurrence. The cohort size and number of events did not
allow for the inclusion of additional variables. For overall survival, age
was added to the multivariable analysis. All statistical analyses were
performed using SPSS (Version 24.0; IBM, Chicago, IL) and the survival
curves were plotted using GraphPad Prism (version 8.0; Graphpad Inc,
La Jolla, CA).
3 | RESULTS
In total, 2095 underwent resection for rectal cancer in 2011 in
The Netherlands and were included in the snapshot study cohort.
Eighty‐seven patients underwent emergency surgery and were ex-
cluded. A further 134 patients were excluded due to M1 disease.
Finally, 326 patients were excluded due to either undetermined or
missing cN category (n = 293) and/or pN category (n = 43). Baseline
characteristics of the 1548 included patients are shown in Table 1.
3.1 | Staging
Out of 695 patients (45%) who were staged cN0, 135 (19%) were
postoperatively staged as (y)pN1 and 33 (5%) as (y)pN2. Out of the
594 (38%) patients staged cN1, 65 patients (11%) were staged (y)
pN2 after surgery. Out of the entire cohort, 233 (15%) of patients
had a higher (y)pN category than the preoperative cN category.
Upfront surgery without neoadjuvant treatment was performed
in 131 patients (8%). The majority had cN0 disease (84 [64%]), of
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which 20 (24%) were ultimately staged pN1 and 5 (6%) pN2 (Table 2).
A further 38 patients were staged cN1, of whom 5 (16%) were pN2.
This resulted in 31 (24%) patients with a higher pN compared to the
preoperative cN category in patients who underwent surgery alone.
Neoadjuvant treatment consisted of short‐course radiotherapy
(5 × 5 Gy) in 744 patients (48%), with a short interval to surgery
in 678 patients (91%) and long interval in 66 patients (9%). Of the
411 patients with a short interval to surgery after 5 × 5 Gy and a cN0
category, 87 (21%) were ypN1 and 19 (5%) ypN2. An unexpected
ypN2 category was found in 29 patients (12%) out of the 243 cN1
patients. This amounted to 135 (20%) understaged patients who
underwent short‐course radiotherapy before surgery.
There was a trend towards less lymph node understaging by the
use of MRI. Understaging (ie, a pN category higher than the cN
category) occurred in 21 out of the 95 (22%) without a preoperative
MRI, compared to 210 out of the 1435 patients (17%) having MRI
(P = .054). For the remaining 18 patients, it was unknown whether a
preoperative MRI was performed.
3.1.1 | Local recurrence and survival
Overall local recurrence rate at 36 months was 5%. These rates were
similar for cN0, cN1, and cN2 staged patients, being 6%, 5%, and 5%,
respectively (Figure 1A). The pathological N‐category was more
predictive for local recurrence rate at 36 months: 4%, 5%, and 15%
for (y)pN0, (y)pN1, and (y)pN2, respectively (Figure 1B). Local
recurrence rate was 8% at 36 months after upfront surgery, 2% after
short‐course radiotherapy with a short interval to surgery, and 6%
after chemoradiotherapy followed by surgery.
Multivariable analysis revealed that for patients with (y)pN1
disease, short‐course radiotherapy before surgery was associated
with lower local recurrence rates (Table 3). Underestimated cN
category was not predictive for local recurrence. For patients with a
(y)pN2‐category, multivariable analysis identified only advanced
T‐category to be associated with local recurrence, and short‐course
radiotherapy before surgery approached statistical significance
(Table 3).
Distant metastasis‐free survival was 81% at 36 months after
surgery. The rates were 84%, 79%, and 77% for cN0, cN1, and cN2,
respectively, and 88%, 66%, and 62% for (y)pN0, (y)pN1, and (y)pN2,
TABLE 1 Patient and disease characteristics
n = 1548
Age, median (IQR) 67 (60‐75)
Male sex, n (%) 984 (64)
ASA score, III or IV, n (%) 256 (17)
Distance to anal verge, n (%)
<3 cm 358 (23)
3.1‐7.0 cm 445 (29)
>7 cm 423 (27)
Preoperative MRI, n (%) 1435 (93)









Mesorectal margin <1mm, n (%) 433 (28)
Neoadjuvant therapy, n (%)
None 131 (9)
5 ×5 Gy, short interval 678 (44)




Low anterior resection 766 (50)
Abdominoperineal resection 472 (31)
Low Hartmann 272 (18)
Other 38 (2)
Laparoscopy, n (%) 754 (49)











Abbreviation: IQR, interquartile range.
TABLE 2 pathological N‐category according to clinical N‐category
No neoadjuvant treatment
cN0 cN1 cN2
(y)pN0 59 (70) 16 (42) 6 (67)
(y)pN1 20 (24) 16 (42) 1 (11)
(y)pN2 5 (6) 1 (11) 2 (22)
5×5 Gy—short interval
(y)pN0 305 (74) 126 (52) 14 (58)
(y)pN1 87 (21) 88 (36) 4 (17)
(y)pN2 19 (5) 29 (12) 6 (25)
Chemoradiotherapy
(y)pN0 93 (84) 151 (64) 111 (63)
(y)pN1 11 (10) 68 (29) 40 (23)
(y)pN2 7 (6) 19 (8) 25 (14)
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respectively (Figure SIA,B). The metastasis‐free survival was 80% for
patients who underwent upfront surgery, 85% after short‐course
radiotherapy with a short interval to surgery and 75% after
chemoradiotherapy followed by surgery. At multivariable analysis,
clinical nodal understaging had no impact on the rate of metastasis‐
free survival, neither in patients staged (y)pN1, nor for those staged
(y)pN2 (Table SI).
Overall survival at 3 years was 81%, which was similar for all cN
categories (cN0 82%, cN1 82%, and cN2 78%), but dependent on the
pN category ((y)pN0 85%, (y)pN1 79%, and (y)pN2 58%, P < .001)
(Figure 2A,B). Three‐year overall survival after upfront surgery was
72%, which was 85% and 82% after short‐course radiotherapy and
chemoradiotherapy, respectively (P < .001).
There was no effect of clinical nodal understaging on 3‐year
overall survival in patients staged (y)pN1:77%, 79%, and 83%, for
cN0, 1, and 2, respectively (P = .388) (Figure 2C). The majority of
these patients underwent either short‐course radiotherapy (47%
[179/381]) or chemoradiotherapy (31% [119/381]) before surgery,
but in none of these subgroups a survival difference was found. In
patients staged (y)pN2, the overall survival was similar for those
staged cN0‐1 and cN2 (70% and 48%, respectively) (Figure 2D). In
multivariable analysis, an underestimated cN category was not
associated with overall survival, neither in (y)pN1, nor in patient
staged (y)pN2 (Table SII).
4 | DISCUSSION
In a cohort of 1548 patients who underwent surgical resection for
rectal cancer in 2011 in The Netherlands, 233 patients (15%)
were clinically understaged considering the actual postoperative
lymph node category. Clinical lymph node understaging had no
significant impact on local recurrence rates, did not impact
metastasis‐free survival, and was not associated with lower
overall survival rates.
Several randomized trials have shown the prognostic significance
of local lymph node metastases on local recurrence rates which was
confirmed in the nationwide data.16‐19 Two large meta‐analyses















































































F IGURE 1 Local recurrence‐free survival according to (A) cN category and (B) (y)pN category. Curves were generated according to the
Kaplan‐Meier methods, differences between groups were tested using logrank tests, and numbers of patients at risk are depicted
below the graphs [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 3 Multivariable analysis for local recurrence in patients
staged (y)pN1, and (y)pN2
(y)pN1
Hazard ratio






Chemoradiotherapy 0.47 (0.12‐1.88) .285
Other 1.49 (0.43‐5.17) .534
Underestimated cN category,
cN < (y)pN stage
1.67 (0.68‐4.12) .263
pT‐category, pT3‐4 vs pT0‐2 1.42 (0.96‐2.10) .075
Tumor positive resection margin 2.08 (0.65‐6.72) .192
(y)pN2
Hazard ratio






Chemoradiotherapy 0.39 (0.09‐1.58) .186
Other 1.38 (0.39‐4.83) .615
Underestimated cN category,
cN < (y)pN stage
1.91 (0.75‐4.84) .175
pT‐category, pT3‐4 vs pT0‐2 1.58 (1.15‐4.83) .004
Tumor positive resection margin 22.21 (0.69‐7.12) .184
Abbreviation: CI, confidence interval.
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evaluated the accuracy of endoscopic ultrasound, CT, and MRI for
nodal staging. One included 90 studies and found similar accuracy for
all modalities, but with a limited sensitivity that did not exceed 67%.9
The other with 75 articles found a slight but nonsignificant advantage
for endoscopic ultrasound.20 The reported sensitivity for the detec-
tion of nodal disease ranged from 57% to 85%, meaning positive
nodes were overlooked in one out over every two to seven patients.
Size alone was insufficient to discriminate tumor positive nodes on
MRI, contour and signal intensity have been shown to increase
discrimination.21‐23 Up to 58% of positive nodes were less than 5mm,
negative nodes more than 10mm were not uncommon and in
patients with positive nodes concurrent reactive nodes were often of
similar or even greater size.21,22 Combining size with the morpho-
logical criteria increased the accuracy but to the limited extent
mentioned above.
In The Netherlands, nodal status is one of the criteria for the
selection of patients for the most appropriate neoadjuvant treatment
regimen. Almost all randomized rectal cancer trials on neoadjuvant
treatment did not incorporate routine MRI staging. Several studies
have reported that node positive disease was a risk factor for local
recurrence.10,24 The Dutch TME trial showed that short‐course
radiotherapy reduced local recurrence at 2 years by over threefold at
univariable analysis.10 A similar Swedish trial also revealed a twofold
reduction in local recurrence by preoperative short‐course radio-
therapy in node positive disease.25 These results indicated that
patients understaged as cN1 at preoperative MRI and who did not
undergo short‐course radiotherapy were at increased risk of local
recurrence. Whether MRI staging can improve risk stratification
beyond the clinical staging as used in these previous trial remains to
be investigated in future trials. Furthermore, quality of TME surgery
has significantly improved over time, which has diminished the ab-
solute risk reduction that can be obtained by adding neoadjuvant
radiotherapy. The overall rate of positive resection margins in the
TME trial was 15%, while the current rate of incomplete resection is
below 10% overall, and below 5% for early to intermediate risk rectal
cancer without neoadjuvant radiotherapy.26‐28
Patients with a preoperative underestimated lymph node stage
did not have inferior local recurrence rates or overall survival. This
observation leaves open to the current use of preoperative nodal
category to select patients for neoadjuvant treatment. Especially
considering that in other countries such as the UK, lymph node status
does not dictate neoadjuvant treatment.29 With more accurate































































































































F IGURE 2 Overall survival according to (A) cN category and (B) (y)pN category. Overall survival in patients with (y)pN1 according to cN category
is shown in (C) and for (y)pN2 patients in (D). Curves were generated according to the Kaplan‐Meier methods, differences between groups were
tested using logrank tests, and numbers of patients at risk are depicted below the graphs [Color figure can be viewed at wileyonlinelibrary.com]
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diagnostic imaging and more reliable preoperative identification of
positive lymph nodes, the true impact of positive lymph nodes in
rectal cancer might become apparent. However, considering the
overall low local recurrence rate of 5% at 3 years after surgery in the
current cohort, a trial to further reduced local recurrence rate will
require a very large sample size. Furthermore it should be mentioned
that only a small number of patients did not receive any neoadjuvant
therapy. This can also contribute to the similar recurrence rates
found in patients with preoperative underestimated nodal status.
A significant proportion of local recurrences arise from enlarged
lateral lymph nodes, which are not completely eradicated by che-
moradiotherapy and not resected with TME. Lateral lymph node
dissection in case of enlarged lateral lymph nodes on a preoperative
MRI could possibly help reduce local recurrence rates. Monitoring
the effects in a trial on such intervention will require standardized
reporting using currently absent consensus criteria for suspicious
lymph nodes.30,31 Developments in the field of MRI such as
nanoparticle‐enhanced MRI can also increase the diagnostic
accuracy,32 but eliminating subjectivity towards suspicious lymph
nodes through automated analyses of MRI images using deep
learning techniques should also be subject of future research.33
Unexpectedly positive lymph nodes suggests the use of adjuvant
therapy. Adjuvant therapy after resection with positive circumferential
margin seems to have no benefit.34 Some studies do suggest a
reduction in local recurrence rates with adjuvant therapy for high‐risk
patients who did not receive neoadjuvant treatment.35‐37 However
this subject is controversial, and considering the low overall local
recurrence rates would result in substantial overtreatment. Due to the
probable high number of patients needed to treat, the benefits are
unlikely to outweigh the negative side effects of adjuvant therapy.
As the criteria for positive lymph nodes on MRI images are not
unequivocal, not only understaging, but also overstaging is a problem.
Although analyzing overstaging was not the aim of the analysis,
Table 2 shows it does occur. Although the numbers are small, due to
the neoadjuvant therapies that hamper analyses on overstaging, it is
a problem discussed in literature.38,39 Overstaging can lead to un-
necessary neoadjuvant treatment that might not offer a benefit, but
does do harm. Short‐course radiotherapy is associated with more
frequent fecal incontinence, sexual problems, and delayed wound
healing.40‐43
The large national cross‐sectional study design is a strength of
the present study. The limitations include the retrospective data
collection. Due to the voluntary participation, not all Dutch hospitals
(71/94) contributed data. Nevertheless the cross‐sectional design
provided data representing daily clinical practice. Also the neoadju-
vant treatment regimens do not allow complete correlation of cN and
pN category due to possible tumor regression. Only a minority of
patients received surgery alone at the time rectal cancer was
significantly overtreated with radiotherapy in the Netherlands.44 In
the 2014 revised Dutch guideline, radiotherapy was no longer
recommended for low risk rectal cancers. Furthermore, MRI criteria
were introduced to assess mesorectal lymph node status. It would
therefore be very insightful to repeat this analysis for current Dutch
practice. Finally, other negative predictive factors that can be
extracted from MRI imaging, such as extramural vascular invasion,
were not available in the current dataset, while these might be able
to explain some differential outcomes.45
In conclusion, understaging of nodal status is not uncommon but
not associated with higher rates of (local) recurrence or inferior
overall survival. Although the overall outcomes of the cohort were
comparable to large randomized trials, future studies should assess
the effect of preoperative staging accuracy on outcomes with the
current more restricted neoadjuvant therapy indications.
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